Evidence map›Paper›PMID 32520786›Full record

ReviewCurrent opinion in organ transplantation2020

Precision transplant pathology.

Michelle A Wood-Trageser, Qinyong Xu, Adriana Zeevi, Parmjeet Randhawa, Drew Lesniak, Anthony J Demetris

Abstract readReview
In one paragraph

Review in Current opinion in organ transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michelle A Wood-TrageserThomas E. Starzl Transplantation Institute, University of Pittsburgh.
Qinyong XuThomas E. Starzl Transplantation Institute, University of Pittsburgh.
Adriana ZeeviThomas E. Starzl Transplantation Institute, University of Pittsburgh.
Parmjeet RandhawaThomas E. Starzl Transplantation Institute, University of Pittsburgh.
Drew LesniakThomas E. Starzl Transplantation Institute, University of Pittsburgh.
Anthony J DemetrisThomas E. Starzl Transplantation Institute, University of Pittsburgh.

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
Transplant Pathology and Tissue Imaging Core (Core B)U19AI131453 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THOMSON, ANGUS W · 2017 to 2022
$8.4M
Polyclonal Tregs to Promote Tolerance in Pediatric Liver Transplant RecipientsU01AI104347 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FENG, SANDY · 2013 to 2017
$4.8M
PROSPECTIVE LONGITUDINAL STUDY OF IWITH SCREEN FAILURES SECONDARY TO HISTOPATHOLOGYR01DK114180 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FENG, SANDY · 2017 to 2019
$1.3M
NIAID NIH HHS U01 AI104347NIAID NIH HHS U19 AI131453NIAID NIH HHS UM1 AI109565NIDDK NIH HHS R01 DK114180
6 · The paper itself

Abstract

purpose of reviewTransplant pathology contributes substantially to personalized treatment of organ allograft recipients. Rapidly advancing next-generation human leukocyte antigen (HLA) sequencing and pathology are enhancing the abilities to improve donor/recipient matching and allograft monitoring. RECENT

findingsThe present review summarizes the workflow of a prototypical patient through a pathology practice, highlighting histocompatibility assessment and pathologic review of tissues as areas that are evolving to incorporate next-generation technologies while emphasizing critical needs of the field. SUMMARY: Successful organ transplantation starts with the most precise pratical donor-recipient histocompatibility matching. Next-generation sequencing provides the highest resolution donor-recipient matching and enables eplet mismatch scores and more precise monitoring of donor-specific antibodies (DSAs) that may arise after transplant. Multiplex labeling combined with hand-crafted machine learning is transforming traditional histopathology. The combination of traditional blood/body fluid laboratory tests, eplet and DSA analysis, traditional and next-generation histopathology, and -omics-based platforms enables risk stratification and identification of early subclinical molecular-based changes that precede a decline in allograft function. Needs include software integration of data derived from diverse platforms that can render the most accurate assessment of allograft health and needs for immunosuppression adjustments.

Indexed as

Histocompatibility TestingHLA AntigensHumansOrgan TransplantationPrecision MedicineTissue DonorsTransplantation, HomologousTransplantation ImmunologyTransplantsHLA Antigens

Identifiers

PMID32520786
PMCPMC7737245

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.